Oncopeptides AB
0.15
EUR
+0.00
(-1.63%)
ISIN
SE0009414576
Return %
Stock
S&P 500
1Y
-64.71
14.20
3Y
-61.05
81.12
5Y
-71.16
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Sofia Heigis
- Full Time Employees
- 75
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Luntmakargatan 46 Stockholm AB Sweden 111 37
- IPO Date
- Feb 22, 2017
- Website
- oncopeptides.se
- Similar Companies
- Business
- Oncopeptides AB (publ) is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological cancers, with a primary focus on multiple myeloma. The company's core product is Pepaxti (melflufen), a peptide-drug conjugate designed to selectively deliver cytotoxic agents into cancer cells through peptidase targeting. Oncopeptides markets Pepaxti primarily for the treatment of relapsed and refractory multiple myeloma and has developed access programs to make the drug available in regions where it is not yet commercially launched. The company leverages its proprietary Peptide Drug Conjugate platform to develop innovative oncology treatments aimed at improving patient outcomes and quality of life. Oncopeptides operates commercially across Europe, including recent market entries into Italy and Spain, and has established partnership agreements to extend its reach into markets such as South Korea, the Middle East, and Africa. The company also collaborates with specialized pharmaceutical distributors like SD Pharma in Spain to broaden physician and hospital access to Pepaxti. Recent strategic developments include the formal approval of full reimbursement for Pepaxti in Italy and Spain, underpinning ongoing commercialization efforts. The company has also taken strategic steps toward financial strengthening, including a rights issue completed in 2025 to support growth ambitions. However, the company faced regulatory challenges in the United States, with the FDA confirming the withdrawal of Pepaxto (the U.S. branding for melflufen) from the U.S. market. Founded in 2010, Oncopeptides is headquartered in Stockholm, Sweden. The company remains science-driven and entrepreneurial, focused on expanding its product portfolio and geographic footprint through clinical innovation and partnerships. It aims to leverage real-world evidence demonstrating Pepaxti’s efficacy and safety to support its evolving clinical use and to adapt to new lines of treatment within hematology oncology. Oncopeptides continues to explore new markets and collaborations to enhance the commercial uptake of Pepaxti and advance its broader therapeutic pipeline. This description includes the company’s main product offerings, recent financial and operational changes, and geographic and strategic expansions, reflecting its status as a focused biotech player in the hematological cancer treatment space with active commercialization in Europe and partnerships elsewhere.